Transformative long-term weight loss results show 95% of total body weight loss achieved during Elipse Balloon treatment was maintained at one-year
Allurion Technologies has announced new clinical data from two studies on the Elipse Balloon at ObesityWeek 2020. The Allurion Program features the Elipse Balloon, the world’s first and only procedureless weight loss device. The balloon is designed to remain in the stomach for four months and is paired with a Bluetooth connected scale and Allurion smartphone app and a supervised nutritional programme.
In the first study, ‘Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, Dr Roberta Ienca and colleagues report on 509 patients who received the Elipse Balloon and were followed for one year. After four months of Elipse Balloon treatment patients achieved weight loss of 14.4±7.7kg or 13.9±6.4% of total body weight. At one-year follow-up, 95% of this weight loss was sustained.
In the second study, ‘Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximates Bariatric Surgery Results, Ienca and colleagues report on 42 patients treated with sequential Elipse Balloons. Between one and five months following the passing of the first Elipse Balloon, a second balloon was placed. After four months, mean weight loss and percent total body weight loss were 14.7±4.4kg and 14.4±3.6%, respectively. The second balloon resulted in an additional 8.8±5.7kg and 10.0±6.5% weight loss, respectively. In total, sequential balloon treatment resulted in weight loss of 22.0+/-9.0kg or 22.8+/-8.8%, and a BMI decrease of 8.1kg/m2 from baseline.
“Both of these studies demonstrate the potential that the Allurion Program has in providing consumers with long-term and sustainable results,” said Dr Shantanu Gaur, co-founder and CEO of Allurion. “Additionally, this data indicates that consumers can achieve life-changing results without needing to undergo surgery, endoscopy or anaesthesia.”
“The Elipse Balloon provides my patients with a primary weight loss tool and an alternative to weight loss surgery,” said Dr Alberto Pagan, Clinica CINIB, Palma de Mallorca, Spain. “These results underscore how the Allurion Program can deliver both short and long-term results that meet the expectations of my patients.”
“The clinical data presented at Obesity Week is reflective of the increasing demand for our product around the world,” said Benoit Chardon, Executive Vice President Commercial for Allurion. “We have tripled the number of patients treated in the past year and have created a reputation for clinical results that providers and patients can trust.”